跳转至内容
Merck
所有图片(1)

主要文件

SML1222

Sigma-Aldrich

洛匹那韦

≥98% (HPLC)

别名:

(αS)-N-[(1S,3S,4S)-4-[[(2,6-二甲基苯氧基)乙酰基]氨基] -3-羟基-5-苯基-1-(苯基甲基)戊基]四氢-α-(1-甲基乙基)-2-氧代-1(2H)-

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C37H48N4O5
分子量:
628.80
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D -20 to -27°, c = 0.4 in methanol

顏色

white to beige

溶解度

DMSO: 20 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

N4(CCCNC4=O)[C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@@H](NC(=O)COc3c(cccc3C)C)Cc2ccccc2)Cc1ccccc1

InChI

1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1

InChI 密鑰

KJHKTHWMRKYKJE-SUGCFTRWSA-N

正在寻找类似产品? 访问 产品对比指南

應用

洛匹那韦已被用作ZMPSTE24和人类免疫缺陷病毒蛋白酶的抑制剂。

生化/生理作用

洛匹那韦是一种抗病毒HIV蛋白酶抑制剂。 单独洛匹那韦具有不足的生物利用度,因此它通常与HIV蛋白酶抑制剂利托那韦联合用于治疗,利托那韦可抑制细胞色素P450-3A4(CYP3A4),其是一种能够代谢蛋白酶抑制剂的肝酶。洛匹那韦还具有抑制ZMPSTE24(锌金属肽酶STE24)的能力。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

K A Sutherland et al.
The Journal of antimicrobial chemotherapy, 70(1), 243-248 (2014-09-18)
PI susceptibility results from a complex interplay between protease and Gag proteins, with Gag showing wide variation across HIV-1 subtypes. We explored the impact of pre-treatment susceptibility on the outcome of lopinavir/ritonavir monotherapy. Treatment-naive individuals who experienced lopinavir/ritonavir monotherapy failure
Translocon Declogger Ste24 Protects against IAPP Oligomer-Induced Proteotoxicity.
Kayatekin C, et al.
Cell, 173(1), 62-73 (2018)
H L Sham et al.
Antimicrobial agents and chemotherapy, 42(12), 3218-3224 (1998-12-03)
The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using the X-ray crystal structure of the complex of HIV protease
Didier K Ekouevi et al.
BMC infectious diseases, 14, 461-461 (2014-08-27)
Few data are available on antiretroviral therapy (ART) response among HIV-2 infected patients. We conducted a systematic review on treatment outcomes among HIV-2 infected patients on ART, focusing on the immunological and virological responses in adults. Data were extracted from
Camille Fraichard et al.
International journal of molecular sciences, 22(2) (2021-01-16)
Protease Inhibitors (PI e.g., ritonavir (RTV) and lopinavir (LPV)) used to treat pregnant mothers infected by HIV induce prematurity and endocrine dysfunctions. The maintenance of pregnancy relies on placental hormone production (human Chorionic Gonadotrophin (hCG) and progesterone (P4)). Those functions

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门